Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo

Cancer Research

Volumn 61, Issue 20, 2001, Pages 7501-7506

  Bello, Lorenzo ^a   Carrabba, Giorgio ^a   Giussani, Carlo ^a   Pluderi, Mauro ^a   Tomei, Giustino ^a   Villani, Roberto ^a   Lucini, Valeria ^a   Cerutti, Francesca ^a   Scaglione, Francesco ^a   Carroll, Rona S ^b   Black, Peter Mcl ^b   Landré, Julien ^c   Bikfalvi, Andreas ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; GELATINASE A; PEPTIDE FRAGMENT; RECOMBINANT PEX; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MIXTURE; GLIOMA; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; GLIOBLASTOMA; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035887463     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Primary glial tumor patients treated by combining cis-platin and etoposide
2. Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma
3. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A Phase II study
4. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors
5. Response of brain tumors to chemotherapy, evaluated in a clinically relevant xenograft model
6. Angiostatin suppresses malignant glioma growth in vivo
7. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
8. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth
9. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy
10. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms
11. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
12. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents
13. The concept of continuous low dose (metronomic) anti-angiogenic chemotherapy
14. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
15. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: Effects on tumor neovascularization
16. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic diseases
17. Anti-angiogenesis is produced by nontoxic doses of vinblastine
18. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression
19. Different signal transduction properties of KDR and flt-1, two receptors for VEGF
20. Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents
21. Interaction of cis-diamminedichloro-platinum (II) and its analogues cis-1,1-cyclobutanedicarboxylato(2R)-2-methyl-1,4-butanediammineplatinum (II) and cis-diammine (glycolato)platinum with hyperthermia in vivo
22. Synergy of the combination of nedaplatin with etoposide in murine and human lung carcinoma